Envafolimab as First-line Treatment of Aged Patients in Advanced NSCLC

Summary

Explore the efficacy and safety of Envafolimab in first line treatment of elderly patients with locally advanced or metastatic non-small cell lung cancer with high PD-L1 expression, view to providing better treatment options for elderly patients with high PD-L1 expression and improving the survival and prognosis of patients .

Timeline

Start

2021-08-30

Primary completion

2024-12-30

Completion

2025-06-30

Drugs

Indications